Group 1 - The company Jiutian Pharmaceutical (SZ 300705) announced that its 15th meeting of the 4th board of directors was held on November 17, 2025, to review documents including proposals for external investments [1] - For the first half of 2025, Jiutian Pharmaceutical's revenue composition was as follows: 82.47% from pharmaceutical preparations, 7.65% from raw materials, 6.03% from pharmaceutical excipients, 3.16% from plant extracts and others, and 0.63% from technology transfer and services [1] - As of the report date, Jiutian Pharmaceutical's market capitalization was 8.4 billion yuan [1]